Related Experiment Video
Updated: Oct 29, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Novel Post-Translational Modifications and Molecular Substrates in Glioma Identified by Bioinformatics
Devasahayam Arokia Balaya Rex1, Sumaithangi Thattai Arun Kumar1, Akhila Balakrishna Rai1
1Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, India.
Abstract:
Glioma is the most common type of brain cancer that originates from the glial cells. It constitutes about one-third of all brain cancers. Recently, transcriptomics, proteomics, and multiomics approaches have been harnessed to discover potential biomarkers and therapeutic targets in glioma. Moreover, post-translational modifications (PTMs) of proteins play a major role in cell biology and function and offer new avenues of research in cancer. Using unbiased multi-PTM bioinformatics analyses of two proteomic datasets of glioma available in the public domain, we identified 866 proteins with common PTMs from both studies. Out of these 866 proteins, 19 proteins were identified with the common PTMs, with the same site modifications pertaining to glioma. Importantly, the identified PTMs belonged to proteins involved in integrin PI3K/Akt/mTOR, JAK/STAT, and Ras/Raf/MAPK pathways. These pathways are essential for cell proliferation in tumor cells and thus involved in glioma progression. Taken together, these findings call for validation in larger datasets in glioma and brain cancers and with an eye to future drug discovery and diagnostic innovation. Bioinformatics-guided discovery of novel PTMs from the publicly available proteomic data can offer new avenues for innovation in cancer research.
Insights
This study identifies 19 key proteins with common post-translational modifications (PTMs) in glioma, offering new targets for brain cancer diagnosis and drug discovery. These findings highlight PTMs
Area of Science:
- Oncology
- Proteomics
- Bioinformatics
Background:
- Glioma, a common brain cancer originating from glial cells, accounts for one-third of all brain cancers.
- Proteomics and multiomics approaches are increasingly used to identify glioma biomarkers and therapeutic targets.
- Post-translational modifications (PTMs) significantly influence protein function and are crucial in cancer research.
Purpose of the Study:
- To identify common post-translational modifications (PTMs) in glioma using multi-PTM bioinformatics analysis.
- To uncover potential diagnostic and therapeutic targets for glioma by analyzing proteomic datasets.
Main Methods:
- Unbiased multi-PTM bioinformatics analysis of two publicly available glioma proteomic datasets.
- Identification of proteins with common PTMs across both datasets.
- Analysis of specific PTM site modifications within identified proteins relevant to glioma.
Main Results:
- Identified 866 proteins with common PTMs from the two glioma proteomic datasets.
- Pinpointed 19 specific proteins exhibiting common PTMs and identical site modifications relevant to glioma.
- These PTMs are associated with key signaling pathways (integrin PI3K/Akt/mTOR, JAK/STAT, Ras/Raf/MAPK) crucial for glioma progression.
Conclusions:
- Bioinformatics analysis of public proteomic data reveals novel PTMs in glioma.
- The identified PTMs in critical signaling pathways represent potential targets for future drug discovery and diagnostic innovation in glioma.
- Further validation in larger datasets is recommended for broader application in brain cancer research.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
05:45Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017